For instance, the administration of an anti-CD200R agonist (OX110) potentiated the anti-tumor effects of R848, a Toll-like receptor 7 (TLR7) agonist, and significantly reduced tumor volume and growth in colon carcinoma murine models. This evidence concerns the gene CD200R1 and neoplasm.